Active, not recruitingPhase 2NCT03047135

Olaparib in Men With High-Risk Biochemically-Recurrent Prostate Cancer Following Radical Prostatectomy, With Integrated Biomarker Analysis

Studying Multiple endocrine neoplasia

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Principal Investigator
Catherine H Marshall, MD
Johns Hopkins University
Intervention
Olaparib(drug)
Enrollment
51 enrolled
Eligibility
18 years · MALE
Timeline
20172027

Study locations (4)

Collaborators

AstraZeneca

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT03047135 on ClinicalTrials.gov

Other trials for Multiple endocrine neoplasia

Additional recruiting or active studies for the same condition.

See all trials for Multiple endocrine neoplasia

← Back to all trials